Cargando…

Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors

BACKGROUND: Genetic alterations are common in non-small cell lung cancer (NSCLC), and DNA mutations and translocations are targets for therapy. Copy number aberrations occur frequently in NSCLC tumors and may influence gene expression and further alter signaling pathways. In this study we aimed to c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bjaanæs, Maria Moksnes, Nilsen, Gro, Halvorsen, Ann Rita, Russnes, Hege G., Solberg, Steinar, Jørgensen, Lars, Brustugun, Odd Terje, Lingjærde, Ole Christian, Helland, Åslaug
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501630/ https://www.ncbi.nlm.nih.gov/pubmed/34625038 http://dx.doi.org/10.1186/s12885-021-08811-7

Ejemplares similares

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma—differences in histological subtypes
por: Eide, Hanne A., et al.
Publicado: (2016)

The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery
por: Öjlert, Åsa Kristina, et al.
Publicado: (2019)

Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
por: Haakensen, Vilde D., et al.
Publicado: (2020)

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2014)

Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
por: Nordgård, Oddmund, et al.
Publicado: (2013)

Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
por: Halvorsen, Ann Rita, et al.
Publicado: (2019)

Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
por: Halvorsen, Ann Rita, et al.
Publicado: (2020)

Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
por: Turzer, Martin, et al.
Publicado: (2010)

Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people
por: Nilssen, Yngvar, et al.
Publicado: (2023)

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
por: McGowan, Marc, et al.
Publicado: (2017)

Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non-Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity
por: Turzer, Martin, et al.
Publicado: (2011)

Osteopontin is a prognostic biomarker in non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2013)

EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
por: Shao, Borong, et al.
Publicado: (2019)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
por: Khadse, Anand, et al.
Publicado: (2022)

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
por: Halvorsen, Ann R., et al.
Publicado: (2016)

NUT expression in primary lung tumours
por: Lund-Iversen, Marius, et al.
Publicado: (2015)

A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
por: Halvorsen, Ann Rita, et al.
Publicado: (2016)

Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
por: Berg, Janna, et al.
Publicado: (2021)

Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
por: Berg, Janna, et al.
Publicado: (2018)

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
por: Joly-Battaglini, Albane, et al.
Publicado: (2016)

The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
por: Frafjord, Astri, et al.
Publicado: (2021)

Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors
por: Rye, Inga H., et al.
Publicado: (2018)

High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival
por: Baumbusch, Lars O., et al.
Publicado: (2013)

Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
por: Eide, Hanne Astrid, et al.
Publicado: (2016)

GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
por: Trinh, Anne, et al.
Publicado: (2014)

DNA copy number motifs are strong and independent predictors of survival in breast cancer
por: Pladsen, Arne V., et al.
Publicado: (2020)

A NOTCH added to metabolomics
por: Brustugun, Odd Terje
Publicado: (2019)

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
por: Eide, Hanne A., et al.
Publicado: (2018)

Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2012)

Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial
por: Horndalsveen, Henrik, et al.
Publicado: (2022)

The multitude of molecular analyses in cancer: the opening of Pandora’s box
por: Russnes, Hege G, et al.
Publicado: (2014)

Genomic aberrations in borderline ovarian tumors
por: Micci, Francesca, et al.
Publicado: (2010)

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
por: Haakensen, Vilde Drageset, et al.
Publicado: (2021)

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2022)

GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
por: Lyng, Heidi, et al.
Publicado: (2008)

Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 – 2020 - A population-based registry study from Norway
por: Børø, Siri, et al.
Publicado: (2022)

Linear and non-linear dependencies between copy number aberrations and mRNA expression reveal distinct molecular pathways in breast cancer
por: Solvang, Hiroko K, et al.
Publicado: (2011)

Breast tumor copy number aberration phenotypes and genomic instability
por: Fridlyand, Jane, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_22ifkbq8nebfc3r5m57ahvht4b